Drugs / 304
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03980379 | Dec 2018 → Jun 2019 | B-cell non-Hodgkin lymphoma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03980379 ↗ |
| Route | Intravenous | “304 injection.WILL be administered single dose IV” NCT03980379 ↗ |